Single-Manager Hedge Funds: The Best Way to Get a Recurring Guest Spot on CNBC?
Mergers and Inquisitions
JANUARY 31, 2024
In-depth analysis that might take days or weeks, such as a financial model with 1,000 rows in Excel to assess a biopharma company’s valuation. Also, most of its outperformance came from strong results in 2004 – 2010, which is why it struggled and lost AUM and investor support in the 2011 – 2019 period.
59 
Let's personalize your content